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Previewsseems to be no consequences for cre-
specific T cells expression there. This
seems to be a state of immunological
ignorance, and a puzzle as to just
how one protects against autoimmunity
in such cases. Perhaps the answer is
that there is yet another, unknown mech-
anism promoting tolerance in organs of
this type.
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How inflammatory caspases trigger pyroptotic cell death is mostly unexplained. In this issue of Immunity,
Nu´n˜ez and colleagues report that caspase-11 cleaves the transmembrane channel pannexin-1, causing an
efflux of cellular ATP that promotes a P2X7 receptor-dependent pyroptosis.The term pyroptosis was coined to
describe a proinflammatory form of cell
death (Bergsbaken et al., 2009). It is
derived from the Greek roots pyro, mean-
ing fire, and ptosis, which denotes falling
and matches the terms used for other
forms of programmed cell death. MLKL
pseudokinase phosphorylation or loss of
mitochondrial integrity, which are hall-
marks of necrotic or apoptotic cell death
respectively, are not required for pyropto-
sis. Instead, this pathway is defined by
the activation of inflammatory caspases,
cell swelling, and rapid destabilization
of plasmamembrane integrity. This results
in the release of cellular content including
danger-associated molecular patterns
(DAMPs) and cytokines that mount a
robust inflammatory response. Pyroptosis
can also contribute to the clearance
of intracellular bacteria; by disrupting
infected cells it can release pathogens,
making them susceptible to phagocy-
tosis, andkillingbyneutrophils (Jorgensen
and Miao, 2015).
Initiation of pyroptosis requires at
least one member of the inflammatorycaspases, a family of proteases including
caspase-1 and caspase-11 in mice and
caspase-1, caspase-4, and caspase-5 in
humans. These enzymes resemble the
initiator caspases involved in apoptosis
but are unable to process the many sub-
strates associated with initiation and
execution of apoptotic cell death; in fact,
only a few inflammatory caspases sub-
strates have been described so far.
Inflammatory caspases are activated
within high molecular weight complexes
known as inflammasomes. Caspase-1 in-
flammasomes typically assemble upon
oligomerization of a scaffold protein that
directly or indirectly senses activating
stress signals or pathogen signatures.
Beyond their role in promoting pyroptosis,
caspase-1 inflammasomesarewell known
for their involvement in the maturation of
the pro-inflammatory cytokines IL-1b and
IL-18, an activity that cannot be fulfilled
directly by caspase-11. The caspase-11
inflammasome, also known as the non-
canonical inflammasome, is formed upon
cytosolic exposure of lipopolysaccharide
(LPS), a bacterial component that bindsand directly activates mouse caspase-
11, as well as the two human paralogues
caspase-4 and caspase-5. Activation of
the caspase-11 inflammasome has been
described as the main pathway involved
in LPS-induced lethality in mice, suggest-
ing that pyroptosis might contribute to in-
flammatory syndromes in vivo.
Because the proteolytic activity of
the inflammatory caspases is required
to initiate pyroptosis, it is likely that the
cleavage of at least one of their substrate
promotes cell death. Yet, little is known on
the proteolytic activities that might initiate
the cascade of events associated with
pyroptotic cell death.
A study in this issue of Immunity (Yang
et al., 2015) sheds new light on the
initial steps of pyroptosis. The groups of
Gabriel Nu´n˜ez and Quin Liu describe the
cleavage of pannexin-1 as a pyroptosis-
initiating event.
Pannexin-1 is a plasma membrane
channel widely expressed in diverse tis-
sues. It forms pore channels that
allow the passage of small molecules
such as ions and nucleotides betweenovember 17, 2015 ª2015 Elsevier Inc. 835
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Figure 1. Model of Caspase-11 Mediated P2X7 Pyroptosis
The caspase-11 inflammasome is activated by the delivery of LPS molecules in the cytoplasm. Oligo-
merization of caspase-11 triggers its proteolytic activity that cleaves off the C-terminal portion of the
membrane channel pannexin-1. Upon cleavage, the pannexin-1 channels open and contribute to ATP
release and potassium efflux. Concurrently, cytoplasmic LPS primes, by an unknown mechanism, the
ATP-gated P2X7 receptors. These receptors become sensitive to the nanomolar concentrations of ATP
released by pannexin-1. They form pores at the membrane that eventually cause membrane rupture and
the release of cellular content, including the DAMPs driving inflammation.
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Previewsthe cytoplasm and the extracellular space
(Adamson and Leitinger, 2014). Pannexin-
1 has been studied in a broad range of
physiological responses including macro-
phage and T cell activation. Importantly, it
has also been identified as a key channel-
releasing ATP during apoptosis (Chekeni
et al., 2010). In apoptotic cells, pan-
nexin-1 activation occurs upon degrada-
tion of its C-terminal inhibitory portion
by the effector caspases, caspase-3 and
caspase-7. Apparently, the same cleav-
age site is targeted by caspase-11 (Yang
et al., 2015), indicating that despite
considerable differences in their pheno-
typic and inflammatory features, both
apoptotic and pyroptotic cell death pro-
grams have at least one substrate in com-
mon. In both instances, the cleavage of
pannexin-1 opens its pore promoting the
release of nanomolar concentrations of
ATP. In apoptotic cells, nucleotide release
acts as a signal that contributes to the
clearance of dying cells. In the context
of LPS-mediated caspase-11 activation,
the released ATP activates the ATP-sensi-
tive purinergic receptor P2X7 thereby
promoting P2X7-dependent cytotoxicity
(Yang et al., 2015). When gated to the
open state, the P2X7 proteins form a
channel that facilitates potassium efflux836 Immunity 43, November 17, 2015 ª2015and influx of sodium and calcium. In addi-
tion, depending on the context, the inten-
sity, or the duration of the response, P2X7
can form pores at the membrane that
disrupt its integrity and prompt cytolysis.
P2X7 responds to relatively high concen-
trations of ATP (Bartlett et al., 2014) that
are at least one log higher than the con-
centrations observed upon caspase-11-
mediated pannexin-1 activation. The
amount of ATP released during the initial
phases of pyroptosis therefore appears
incompatible with P2X7 activation. How-
ever, this apparent paradox has been
explained by Yang et al. (2015), who
found that cytosolic LPS dramatically
decreased the threshold of ATP neces-
sary to drive P2X7 opening. The authors
propose that this priming signal licenses
the receptor for pore formation allowing
it to respond to nanomolar concentra-
tions of ATP released when pannexin-1
is processed by caspases (Figure 1).
This regulation of the P2X7 receptor em-
phasizes the specific nature of pyroptosis
and is compatible with the observation
that membrane integrity is not destabi-
lized when low concentrations of ATP
are released, including during apoptosis.
It also suggests that in the course of py-
roptosis, ATP mostly works as an auto-Elsevier Inc.crine signal that targets the cells primed
with a hypersensitive P2X7, sparing the
neighboring cells.
In addition to pyroptosis, the opening of
pannexin-1might contribute to caspase-1
activation. Indeed, pannexin-1 but not
P2X7 is required to mediate some IL-1b
release upon caspase-11 activation. This
could be triggered by pannexin-1 medi-
ated potassium efflux, a signal that can
drive the assembly of the NLRP3 inflam-
masome (Lamkanfi and Dixit, 2014).
Then, pannexin-1 cleavage leads, on one
side, to ATP release and P2X7-dependent
cell death, and on another side to potas-
sium efflux that probably drives NLRP3
dependent IL-1b release.
In a mouse model of sepsis, Yang et al.
(2015) showed that pannexin-1 and P2X7
deficiencies both reduced lethality and
recapitulated the phenotype observed
in caspase-11 knockout mice, while
NLRP3 deficiency did not show any sig-
nificant effect. In contrast, in the same
model, NLRP3 appeared to be necessary
for IL-1b release, whereas P2X7 was not.
This further demonstrates the physio-
logical relevance of the P2X7-dependent
pyroptosis in vivo, compared to the
probably modest contribution of IL-1b
and the NLRP3-inflammasome in this
model. Interestingly, in a different mouse
model of LPS-induced shock, lethality
was rescued by caspase-11 deficiency
but not by deletion of the Panx1 gene
(Vanden Berghe et al., 2015). While both
studies used the same strain of mice,
Yang et al. (2015) primed the mice with a
non-toxic dose of TLR agonists before
the LPS challenge. It is therefore possible
that these apparently contradictory re-
sults might indicate that different initiation
programs drive pyroptosis depending on
the context.
Until now, the mechanisms by which
caspase-11 dramatically disrupted
cellular integrity and initiated inflammation
have been mysterious. The identification
of pannexin-1 opening by caspase-11
provides new light on the initial event
that contributes to a P2X7-dependent py-
roptosis. Nevertheless, many questions
remain to be resolved. For example, the
mechanisms that might act on P2X7 to
decrease its Km for ATP are unknown.
This priming appears to be caspase-11 in-
dependent (Yang et al., 2015), suggesting
that it might occur independently of the in-
flammasome andmight therefore uncover
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the cytoplasm. This observation also rai-
ses the possibility that regulation of P2X7
sensitivity to ATP might also function in
other circumstances and biological sys-
tems, characterized by P2X7 engagement
in response to apparently low concentra-
tions of ATP.
The mechanism by which P2X7 drives
cytotoxicity is also poorly understood
and will have to be clarified. It needs to
be demonstrated that pore-formation is
sufficient to drive membrane disruption
upon ATP ligation.
Another question remaining in the field
is to understand whether IL-1b release
upon inflammasome activation is a pas-
sive event that relies onmembranedisrup-
tion or an active and regulated mecha-
nism. The fact that upon intracellular LPS
exposure P2X7 deficient macrophages
release IL-1b in absence of pyroptosis
suggests that in some circumstances
IL-1b release can be part of an active pro-
cess. The detailed study of P2X7-deficient
macrophagesmight therefore turn out to a
valuable approach to study possible IL-1b
secretion mechanisms that might occur
independently of cell lysis.
Finally, another caspase-11 substrate,
Gasdermin D, has been identified recently(Kayagaki et al., 2015; Shi et al., 2015). Its
cleaved product has been shown to
initiate a pyroptosis program per se.
However, how it exerts cytotoxic func-
tion remains to be discovered. Future
studies will tell us whether this inflam-
matory caspase substrate co-operates
with pannexin-1 and P2X7 to elicit cell
death or whether it defines an alternative
form of pyroptosis. Similarly, it is unclear
whether caspase-1 mediated pyroptosis
relies on the same substrates as cas-
pase-11. If distinct substrates trigger
different death programs, the question
that might arise is whether these sub-
types of pyroptosis have different in-
flammatory properties.
Pyroptosis-mediated inflammation can
have different outcomes ranging from
healing infections to sepsis and death.
Unlocking the mechanisms regulating
the initiation of pyroptosis are great steps
forward that will bring us on the path to a
better understanding of the physiological
roles of pyroptosis. This will, in the long
run, contribute to the development of
therapeutic strategies aimed at enhancing
the defenses against pathogens and tu-
mors, or when pyroptosis is too strong,
to limit the harmful consequences of
inflammation.Immunity 43, NREFERENCES
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Broadly neutralizing antibodies targeting quaternary epitopes on the apex of the HIV-1 envelope spike are an
attractive vaccine target, yet engineering immunogens that recapitulate such epitopes has proven difficult. In
this issue of Immunity, Andrabi and colleagues (2015) identify an exciting new candidate immunogen that
could initiate the production of these types of antibodies through vaccination.After several years of HIV-1 infection,
subsets of individuals develop broadly
neutralizing antibodies (bnAbs). Ad-
vances in antigen-specific B cell isolation
and single-cell antibody cloning have ledto the characterization of an increasing
number of monoclonal antibodies that
can potently neutralize a wide range
of HIV-1 strains from such subjects.
Passively delivered bnAbs protect againstHIV-1 infection in experimental animal
models, and it is expected that if elicited
by vaccination, they could provide steril-
izing immunity in humans. bnAbs target
four major sites on the HIV-1 envelopeovember 17, 2015 ª2015 Elsevier Inc. 837
